Association of serum TIM-3 and Galectin-9 levels with glaucoma progression: implications for clinical monitoring.

IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
American journal of translational research Pub Date : 2026-08-15 eCollection Date: 2026-01-01 DOI:10.62347/HUVJ6501
Zihui Liu, Zong Wang, Linpin Liu, Bin Tu, Kai Wang
{"title":"Association of serum TIM-3 and Galectin-9 levels with glaucoma progression: implications for clinical monitoring.","authors":"Zihui Liu, Zong Wang, Linpin Liu, Bin Tu, Kai Wang","doi":"10.62347/HUVJ6501","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary open-angle glaucoma (POAG) causes irreversible blindness via retinal ganglion cell loss. Neuroinflammation and immune dysfunction drive its progression, yet the role of the TIM-3/Galectin-9 axis remains unclear.</p><p><strong>Objective: </strong>To investigate the association of serum soluble TIM-3 (sTIM-3) and Galectin-9 levels with the progression of primary open-angle glaucoma (POAG).</p><p><strong>Methods: </strong>This retrospective analysis enrolled POAG patients from our ophthalmology department (January 2022-December 2024). After a minimum 12-month follow-up, participants were categorized as progression or stable based on visual field and optical coherence tomography (OCT) assessments. Healthy controls were age/sex-matched. Recorded clinical variables included IOP, CCT, visual fields, and OCT measures. Baseline concentrations of sTIM-3 and Galectin-9 in serum were determined by ELISA. Multivariate logistic regression assessed independent links between these markers and disease progression, supplemented by trend tests, E-value calculations, and subgroup analyses.</p><p><strong>Results: </strong>The study included 120 POAG patients (52 progression, 68 stable) and 60 healthy controls. Baseline measures were balanced across groups. Both sTIM-3 and Galectin-9 were significantly elevated in progression relative to stable patients and controls (all P < 0.001). Multivariate logistic regression identified sTIM-3 (OR = 2.14, P = 0.004) and Galectin-9 (OR = 3.39, P < 0.001) as independent factors linked to disease progression. Trend analyses revealed dose-response patterns (P for trend = 0.015 and 0.004, respectively). These findings were further corroborated by E-value and subgroup analyses, supporting their robustness.</p><p><strong>Conclusions: </strong>Higher baseline sTIM-3 and Galectin-9 levels correlate independently with POAG progression risk, showing a dose-response pattern. These biomarkers may serve as adjunctive references for risk stratification, although their utility warrants prospective validation with longitudinal sampling.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7306-7319"},"PeriodicalIF":1.8000,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590988/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/HUVJ6501","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Primary open-angle glaucoma (POAG) causes irreversible blindness via retinal ganglion cell loss. Neuroinflammation and immune dysfunction drive its progression, yet the role of the TIM-3/Galectin-9 axis remains unclear.

Objective: To investigate the association of serum soluble TIM-3 (sTIM-3) and Galectin-9 levels with the progression of primary open-angle glaucoma (POAG).

Methods: This retrospective analysis enrolled POAG patients from our ophthalmology department (January 2022-December 2024). After a minimum 12-month follow-up, participants were categorized as progression or stable based on visual field and optical coherence tomography (OCT) assessments. Healthy controls were age/sex-matched. Recorded clinical variables included IOP, CCT, visual fields, and OCT measures. Baseline concentrations of sTIM-3 and Galectin-9 in serum were determined by ELISA. Multivariate logistic regression assessed independent links between these markers and disease progression, supplemented by trend tests, E-value calculations, and subgroup analyses.

Results: The study included 120 POAG patients (52 progression, 68 stable) and 60 healthy controls. Baseline measures were balanced across groups. Both sTIM-3 and Galectin-9 were significantly elevated in progression relative to stable patients and controls (all P < 0.001). Multivariate logistic regression identified sTIM-3 (OR = 2.14, P = 0.004) and Galectin-9 (OR = 3.39, P < 0.001) as independent factors linked to disease progression. Trend analyses revealed dose-response patterns (P for trend = 0.015 and 0.004, respectively). These findings were further corroborated by E-value and subgroup analyses, supporting their robustness.

Conclusions: Higher baseline sTIM-3 and Galectin-9 levels correlate independently with POAG progression risk, showing a dose-response pattern. These biomarkers may serve as adjunctive references for risk stratification, although their utility warrants prospective validation with longitudinal sampling.

血清TIM-3和半乳糖凝集素-9水平与青光眼进展的关系:临床监测的意义
背景:原发性开角型青光眼(POAG)通过视网膜神经节细胞丧失导致不可逆失明。神经炎症和免疫功能障碍驱动其进展,但TIM-3/半乳糖凝集素-9轴的作用尚不清楚。目的:探讨血清可溶性TIM-3 (sTIM-3)和半乳糖凝集素-9水平与原发性开角型青光眼(POAG)进展的关系。方法:回顾性分析我院眼科(2022年1月- 2024年12月)的POAG患者。在至少12个月的随访后,根据视野和光学相干断层扫描(OCT)评估,参与者被分为进展或稳定。健康对照组年龄/性别匹配。记录的临床变量包括IOP、CCT、视野和OCT测量。ELISA法测定血清中sTIM-3和半乳糖凝集素-9的基线浓度。多变量逻辑回归评估了这些标志物与疾病进展之间的独立联系,并辅以趋势检验、e值计算和亚组分析。结果:本研究纳入120例POAG患者(52例进展,68例稳定)和60例健康对照。各组间的基线测量是平衡的。与稳定患者和对照组相比,sTIM-3和Galectin-9在进展过程中均显著升高(均P < 0.001)。多因素logistic回归发现sTIM-3 (OR = 2.14, P = 0.004)和Galectin-9 (OR = 3.39, P < 0.001)是与疾病进展相关的独立因素。趋势分析显示剂量-反应模式(趋势P分别为0.015和0.004)。e值和亚组分析进一步证实了这些发现,支持了它们的稳健性。结论:较高的基线sTIM-3和半乳糖凝集素-9水平与POAG进展风险独立相关,显示出剂量-反应模式。这些生物标志物可以作为风险分层的辅助参考,尽管它们的效用需要纵向抽样的前瞻性验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of translational research
American journal of translational research ONCOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
自引率
0.00%
发文量
552
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书